BeiGene Ltd. ADR BGNE fell more than 7% in premarket trading on Thursday, after AbbVie ABBV Pharmacyclics filed a lawsuit for patent infringement against the biotech firm. Pharmacyclics alleged that BeiGene infringed on Pharmacyclics patent for Imbruvica which treats the same condition. The complaint was filed in Delaware federal court by Pharmacyclics. Brukinsa was approved by the U.S. Food and Drug Administration in January for treating chronic lymphocytic lesions and small lymphocytic lymphoma. BeiGene did not immediately…